Contact: Japan Breast Cancer Research Group

Tokyo 103-0016

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer, CPS-EG Score, Her2-normal, Hormonreceptor Positive, Postneoadjuvant Treatment With CDK 4/6 Inhibitor

Studies at this site

• A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery — Completed